![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington
Breast cancer resistance protein (BCRP) is a recently discovered ATP-binding cassette drug transporter. Hence, the full spectrum of therapeutic agents that interact with BCRP remains to be elucidated. Because human immunodeficiency virus protease inhibitors (HPIs) are well known P-glycoprotein (P-gp) substrates, and there is an overlap in substrate specificity between P-gp and BCRP, this study was performed to investigate whether HPIs are substrates and/or inhibitors of BCRP. First, the effect of HPIs on BCRP efflux activity in human embryonic kidney (HEK) cells stably expressing wild-type BCRP (482R) and its two mutants (482T and 482G) was studied by measuring intracellular mitoxantrone fluorescence using flow cytometry. We found that ritonavir, saquinavir, and nelfinavir were effective inhibitors of wild-type BCRP (482R) with IC50 values of 19.5 ± 0.8 µM, 19.5 ± 7.6 µM, and 12.5 ± 4.1 µM, respectively. Ritonavir, saquinavir, and nelfinavir inhibited 482T and 482G with IC50 values that were approximately 2 times greater than that for 482R. Indinavir and amprenavir had no significant inhibition on BCRP activity. Direct efflux of radiolabeled HPIs in HEK cells was measured to determine whether the HPIs are substrates of BCRP. None of the HPIs were found to be transported by BCRP. Together, ritonavir, saquinavir, nelfinavir, indinavir, and amprenavir are not substrates for BCRP. However, ritonavir, saquinavir, and nelfinavir are effective inhibitors of the transporter. These results suggest that BCRP may play an important role in drug-drug interactions involving coadministration of the HPIs with drugs that are substrates of the transporter.
Address correspondence to: Dr. Qingcheng Mao, Department of Pharmaceutics, School of Pharmacy, Box 357610, University of Washington, Seattle, WA 98195-7610. E-mail: qmao{at}u.washington.edu
This article has been cited by other articles:
|
|
 |
|
  N. Giri, S. Agarwal, N. Shaik, G. Pan, Y. Chen, and W. F. Elmquist Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design Drug Metab. Dispos., March 1, 2009; 37(3): 560 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, M. Leggas, M. Goswami, P. E. Empey, and P. J. McNamara N-(4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine Carboxamide (GF120918) As a Chemical ATP-Binding Cassette Transporter Family G Member 2 (Abcg2) Knockout Model to Study Nitrofurantoin Transfer into Milk Drug Metab. Dispos., December 1, 2008; 36(12): 2591 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Eilers, U. Roy, and D. Mondal MRP (ABCC) Transporters-Mediated Efflux of Anti-HIV Drugs, Saquinavir and Zidovudine, from Human Endothelial Cells Experimental Biology and Medicine, September 1, 2008; 233(9): 1149 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Giri, N. Shaik, G. Pan, T. Terasaki, C. Mukai, S. Kitagaki, N. Miyakoshi, and W. F. Elmquist Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse Drug Metab. Dispos., August 1, 2008; 36(8): 1476 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Usansky, P. Hu, and P. J. Sinko Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats Drug Metab. Dispos., May 1, 2008; 36(5): 863 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, E.-W. Lee, L. Zhou, P. C. K. Leung, D. D. Ross, J. D. Unadkat, and Q. Mao Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells Mol. Pharmacol., March 1, 2008; 73(3): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhou, S. B. Naraharisetti, H. Wang, J. D. Unadkat, M. F. Hebert, and Q. Mao The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study Mol. Pharmacol., March 1, 2008; 73(3): 949 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. van Erp, H. Gelderblom, M. O. Karlsson, J. Li, M. Zhao, J. Ouwerkerk, J. W. Nortier, H.-J. Guchelaar, S. D. Baker, and A. Sparreboom Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib Clin. Cancer Res., December 15, 2007; 13(24): 7394 - 7400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Janneh, E. Jones, B. Chandler, A. Owen, and S. H. Khoo Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes J. Antimicrob. Chemother., November 1, 2007; 60(5): 987 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Matsson, G. Englund, G. Ahlin, C. A. S. Bergstrom, U. Norinder, and P. Artursson A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 19 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kaddoumi, S.-U. Choi, L. Kinman, D. Whittington, C.-C. Tsai, R. J.Y. Ho, B. D. Anderson, and J. D. Unadkat Inhibition of P-glycoprotein Activity at the Primate Blood-Brain Barrier Increases the Distribution of Nelfinavir into the Brain but Not into the Cerebrospinal Fluid Drug Metab. Dispos., September 1, 2007; 35(9): 1459 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pan, N. Giri, and W. F. Elmquist Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine Drug Metab. Dispos., July 1, 2007; 35(7): 1165 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weiss, J. Rose, C. H. Storch, N. Ketabi-Kiyanvash, A. Sauer, W. E. Haefeli, and T. Efferth Modulation of human BCRP (ABCG2) activity by anti-HIV drugs J. Antimicrob. Chemother., February 1, 2007; 59(2): 238 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. G. van Heeswijk, M. Bourbeau, P. Campbell, I. Seguin, B. M. Chauhan, B. C. Foster, and D. W. Cameron Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J. Clin. Pharmacol., July 1, 2006; 46(7): 758 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rautio, J. E. Humphreys, L. O. Webster, A. Balakrishnan, J. P. Keogh, J. R. Kunta, C. J. Serabjit-Singh, and J. W. Polli IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES Drug Metab. Dispos., May 1, 2006; 34(5): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, L. Zhou, A. Gupta, R. R. Vethanayagam, Y. Zhang, J. D. Unadkat, and Q. Mao Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E798 - E807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Meissner, B. Heydrich, G. Jedlitschky, H. Meyer zu Schwabedissen, I. Mosyagin, P. Dazert, L. Eckel, S. Vogelgesang, R. W. Warzok, M. Bohm, et al. The ATP-binding Cassette Transporter ABCG2 (BCRP), a Marker for Side Population Stem Cells, Is Expressed in Human Heart J. Histochem. Cytochem., February 1, 2006; 54(2): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rudek, M. Zhao, N. F. Smith, R. W. Robey, P. He, G. Hallur, S. Khan, M. Hidalgo, A. Jimeno, A. D. Colevas, et al. In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent Clin. Cancer Res., December 1, 2005; 11(23): 8503 - 8511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Vethanayagam, H. Wang, A. Gupta, Y. Zhang, F. Lewis, J. D. Unadkat, and Q. Mao FUNCTIONAL ANALYSIS OF THE HUMAN VARIANTS OF BREAST CANCER RESISTANCE PROTEIN: I206L, N590Y, AND D620N Drug Metab. Dispos., June 1, 2005; 33(6): 697 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Park and P. J. Sinko P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1249 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ford, S. H. Khoo, and D. J. Back The intracellular pharmacology of antiretroviral protease inhibitors J. Antimicrob. Chemother., December 1, 2004; 54(6): 982 - 990. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
